Drug Trial Radar · NCT06777433
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Dec 13, 2024
Primary completion
Apr 23, 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- Radiopharm Theranostics, LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Jan 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single dose, single arm, multicenter Phase 2b study to establish the imaging performance of RAD101 PET in participants who are ≥ 18 years of age and with suspected recurrent brain metastases from solid tumors. The study consists of a 4-week Screening Period, a 3-day Imaging and Safety Follow-Up Period, and a Data Collection Period of up to 6 months. Participant eligibility will be determined during the Screening Period and eligible participants will be enrolled in the study. On Day 1, the enrolled participants will receive a single dose of the investigational medicinal product (IMP), RAD101. Participants will then proceed with a whole brain PET scan. A high-resolution Magnetic Resonance Imaging (MRI) will be performed in joint acquisition with PET or separately on the same day, or on the day prior to or the day following RAD101 administration. For applicable study sites where PK samples will be collected, whole body PET scans will be performed, blood samples will be drawn, and urine will be collected throughout the scanning period. A phone follow-up will be performed on Day 3 (+ 1 day). Participants will have follow-up (longitudinal) MRI (otherwise CT) scans (longitudinal imaging) and/ or a biopsy according to their Standard of Care (SoC). The longitudinal image results, and details of the biopsy if performed as part of SoC (i.e., location and histopathology results), will be collected during the 6- month Data Collection Period.
Conditions
- Brain Metastases From Solid Tumors
Interventions
RAD101 (18F-FPIA)Drug
A single dose of 18F-RAD101 with a maximum of 370 MBq (10 mCi) administered as a slow IV bolus injection over a maximum of 30 seconds, followed by a saline flush.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concordance between RAD101 PET/MRI and MRI with macrocyclic gadoliniumTime frame: 1 Week
- Concordance between RAD101 PET/MRI and MRI with macrocyclic gadoliniumTime frame: 1 Week
- Concordance between RAD101 PET/MRI and MRI with macrocyclic gadoliniumTime frame: 1 Week
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Ascension Illinois Oncology Research
Hoffman Estates, Illinois
Goshen Center for Cancer Care
Goshen, Indiana
University of Michigan
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
BAMF Health
Grand Rapids, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.